FDA Grants Approval for Pantoprazole Sodium ANDA219973
The FDA has granted approval for the ANDA219973 application for Pantoprazole Sodium submitted by Shuangcheng.
Published: July 28, 2026
Updated: July 28, 2026
Author: Humanexa Intelligence
Therapeutic area: Gastroenterology / Proton Pump Inhibitor
Asset: Shuangcheng
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Shuangcheng
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Pantoprazole Sodium ANDA219973 is significant as it allows Shuangcheng to enter the competitive proton pump inhibitor market. This could shift market dynamics and necessitate strategic adjustments from existing competitors.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry strategies and sales performance of Pantoprazole Sodium by Shuangcheng post-approval.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.